NCT05976607Completed
Clinical Study of 18F -FAPI-RGD in Renal Tumor
Linical Study of 18F Labeled Probe Targeting Fibroblast Activating Protein and Integrin avβ3 (FAPI-RGD) in Renal Tumors
Source: ClinicalTrials.gov · Last updated 17 Apr 2025
Brief summary (registry, in English)
The goal of this observational study is to learn about the value of 18F-FAPI-RGD PET/CT imaging in Renal Tumor. Participants will undergo clinical evaluation and 18F-FAPI-RGD PET/CT examination.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 35 (actual)
- First submitted
- 26 Jul 2023
- Start date
- 20 Jun 2023
- Primary completion date
- 15 Jan 2024
- Lead sponsor
- Sichuan Provincial People's Hospital
- Diseases
- Kidney cancer
- NCT number
- NCT05976607
What you commit to
- Study type: Observational
- Participants enrolled: 35
- From 20 Jun 2023 to the primary completion date, 15 Jan 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe liver or kidney disease
Other
- Patients with a second primary tumor
- Pregnant or breastfeeding
- Claustrophobia or other PET/CT scan contraindications
Who the study is looking for
- Age 18 and above
- No gender difference
- Patients who have been diagnosed with, or are clinically highly suspected of, renal tumors and have had no other treatment within 3 months
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Departments of Nephrology, Sichuan Provincial People's Hospital Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.